Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Naason Science operates as a preclinical CRO providing advanced in vitro and in vivo animal models to support early-stage drug discovery across multiple therapeutic areas. They enable pharmaceutical and biotech clients to evaluate candidate drugs' efficacy and safety before clinical trials. The company has published results on the efficacy of FEx‑022 in protecting kidneys during ischemia-reperfusion injury but does not appear to have its own proprietary clinical pipeline advancing into human trials as of June 2025.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Naason Science.